Hagiwara Solutions to Exhibit at SPS 2019
15.11.2019 12:00:00 EET | Business Wire | Press release
Hagiwara Solutions Co., Ltd. (Elecom group) will exhibit at sps – smart production solution from the 26th to 28th of November 2019, Trade Fair Nuremberg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191115005082/en/
Introduction Map (Graphic: Hagiwara Solutions)
|
Hagiwara Solutions Co., Ltd. is with Elecom group which is offering solutions with sensing technologies, industrial computers, and SSDs. D-Clue Technologies Co., Ltd. of Elecom group which is good for sensing technologies will join us at sps. |
SEVEN solutions for your own:
-
Coolant Contamination Detection:
How do you manage machine tool coolant for precise products?
You can maintain the coolant correctly, using our live sensing system.
Let us suggest you make precise products with our coolant contamination detection system.
-
AR Goggle Devices:
How do you browse reference documents during your tasks?
Workers with our AR goggles don’t need to worry about it.
The AR goggle device displays instructions inside of the goggle. Easy to browse instructions during your tasks.
Let us suggest you make your hands free in your factories.
-
Sound Sensing for Connector Mating:
How do your workers recognize their mating connectors correctly?
If they fail to mate them, it must affect your manufacturing processes. Our sound sensing system can pick up just click sounds to make their mating assured.
Let us suggest you reduce assembling failures.
-
umati OPC UA Server on Tiny Gateway:
How do you arrange M2M communications?
Old factory machines can communicate with the other machines on the different platforms, using our gateway certified with umati OPC UA which is the world industrial standard.
Let us suggest you arrange M2M communications freely.
-
Rugged PCs, wherever you work:
What computer is good for your tough working environment?
Our rugged PC, ZEROSHOCK TABLET is good for you.
You must be satisfied with its shock resistant, water and dust resistant, and touch operation with gloves on.
In addition, the thickness is only 13.3mm and the weight is only 795g!
Let us suggest you work wherever you are.
-
Maintenance Free PC Which Diagnoses Itself:
What do you think of a predictive maintenance?
You can see computer troubles before something happens to factory machines which Maintenance Free PC controls.
Let us suggest you say “Unexpected troubles are GONE!”
-
The Robustness of SSDs Under Power Fault:
What should you do in case of power fault in your factory?
You may lose data, your computer systems may be damaged under power fault. Our SSDs can solve it with UWF of Windows10.
Let us suggest you protect your systems and data.
Press briefing:
A press briefing will be held by Mr. Hada, Hagiwara Solutions President as below:
|
Date and time: |
Tuesday, 26th of November, 2019; 4:00 – 5:00 PM |
|
Place: |
|
|
Presenter: |
Mr. Jamie Hada, Hagiwara Solutions President
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191115005082/en/
Contact information
Shinobu Apostol ITO
Hagiwara Solutions Co., Ltd.
pr@hagisol.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom